Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — Investor Presentation (October 2022)
11 slides from Faron Pharmaceuticals Oy's investor presentation, Oct 13, 2022
Slide 1: Bexmarilimab – a macrophage checkpoint to enhance the efficacy of PD-1 blockers
FARON PHARMACEUTICALS OY Bexmarilimab – a macrophage checkpoint to enhance the efficacy of PD-1 blockers October 2022
Slide 2: Corporate Disclaimer
Corporate Disclaimer The contents of this presentation have not been approved by an authorized information and may not be reproduced, re-distributed or passed to any other person within the meaning of Section 21 of the Financial Services and Markets person or published in whole or in part for any pu
Slide 3: Faron in brief
Faron in brief Faron works where PD-1 blockade does not Faron is a clinical stage biopharmaceutical company 2006 Year of foundation focused on building the future of immunotherapy by harnessing the power of the immune system to tackle 2015 & 2019 Listing to London AIM in cancer and inflammation. 201
Slide 4: Bexmarilimab, a CLEVER Antibody with a Lot of Potential
Bexmarilimab, a CLEVER Antibody with a Lot of Potential Potential to disrupt one of the biggest and fastest growing drug markets The Market • Checkpoint inhibitors activating T-cells (namely anti-PD-1s) revolutionized cancer care because they gave a survival benefit in "un-curable cancers" (e.g. lun
Slide 5: Bexmarilimab – The Investment Case
Bexmarilimab – The Investment Case Biotech: de-risked and significant near term read out Clinical data generated in 230 patient trial i) clinical 1 benefit, ii) good safety and tolerability and iii) predicative biomarkers identified Faron plans to produce Phase II combination data with 2 bexmarilima
Slide 6: Synergistic Benefit from Two Different Approaches
Synergistic Benefit from Two Different Approaches As single agents bexmarilimab and anti-PD-1s benefit opposite populations Anti-PD1 treated patients according to IFN gamma status 2,3 Bexmarilimab treated patients according IFN gamm 1.0 0.8 Survival (Probability) The patients, 0.6 who do not benefit
Slide 7: Anti-PD-1 Refractory Melanoma Treated with Single Agent Bexmarilimab
Anti-PD-1 Refractory Melanoma Treated with Single Agent Bexmarilimab Survival of melanoma patients treated with single agent bexmarilimab in Phase I/II • Total population: Last line patients who have received immunotherapy before without any response. All have received single agent BEX in the trial
Slide 8: Clinical Benefit with Bex is Associated with an IFNɣ Response
Clinical Benefit with Bex is Associated with an IFNɣ Response • Patients that benefit from Bex therapy had Lower Immune Activation at Baseline in Patients Achieving Disease Contro low immune activation, indicated by low IFNɣ in blood before therapy. • “Cold” tumors have low immune activation and do
Slide 9: Rationale For Treating with Bex Prior to PD-1 Blockade
Rationale For Treating with Bex Prior to PD-1 Blockade BEX turns Cold Tumors Hot and Triggers the Immune Response anti-PD-1s need BEX Interferon According our clinical findings we can change a cold tumor into a hot tumor. Hot 1) Haslam et al. (2020)tumors JAMA Oncol. 2)are Giuntaresponsive et al. Sc
Slide 10: Summary
Summary Multiple value points • Encouraging results from clinical trials i) survival benefit, ii) good safety and iii) biomarkers • Targeting a large and fast growing market of anti-PD-1; +$30bn, expected to grow to $88bn by 2027 • Addressing a key problem with patients not responding to anti-PD- 1s
Slide 11: Thank You
Thank You | Investor Faron Pharmaceuticals | Non-Confidential Information Presentation
Faron Pharmaceuticals Oy — Investor Presentation (October 2022) on 6ix